Claims for Patent: 7,838,032

Summary for Patent: 7,838,032

Title:	Sustained release of guaifenesin
Abstract:	The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.
Inventor(s):	Davis; Robert D. (Arlington, TX), Blume; Ralph W. (Fort Worth, TX), Keyser; Donald Jeffrey (Southlake, TX)
Assignee:	Reckitt Benckiser Inc. (Parsippany, NJ)
Application Number:	10/406,557
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,838,032
Patent Claims:	1. A drug product comprising guaifenesin and having two portions, wherein a first portion comprises guaifenesin in an immediate release form, which releases guaifenesin in a human's stomach, and a second portion comprises guaifenesin in a sustained release form, wherein the drug product contains 1200 mg of guaifenesin and provides a mean C.sub.max and at least one of a mean AUC.sub.inf and a mean AUC.sub.0-12 for guaifenesin under fasted conditions based on single-dose administration that are from 80% to 125% of the mean C.sub.max and at least one of the mean AUC.sub.inf and the mean AUC.sub.0-12 for guaifenesin provided by a bi-layer tablet containing 1200 mg of guaifenesin and having an immediate release layer consisting essentially of about 210.5 mg of guaifenesin dc, about 117.5 mg of microcrystalline cellulose, about 30 mg of sodium starch glycolate, and about 1 mg of magnesium stearate, and a sustained release layer consisting essentially of about 1052.7 mg of guaifenesin dc, about 25 mg of hydroxypropyl methyl cellulose, about 12.5 mg of carbomer 934P, about 5.7 mg of magnesium stearate, and a colorant, and wherein guaifenesin is absorbed into bloodstream such that the drug product can be appropriately dosed once in a 12-hour period. 2. The drug product according to claim 1, wherein the mean C.sub.max and at least one of the mean AUC.sub.inf and the mean AUC.sub.0-12 for guaifenesin provided by the drug product are from 80% to 125% of the mean C.sub.max and at least one of the mean AUC.sub.inf and the mean AUC.sub.0-12 for guaifenesin provided by the bi-layer tablet at a 90% confidence interval. 3. The drug product according to claim 1, wherein the first and second portions are discrete. 4. The drug product according to claim 3, which is in a form of a bi-layer tablet. 5. A drug product comprising guaifenesin and having two portions, wherein a first portion comprises guaifenesin in an immediate release form, which releases guaifenesin in a human subject's stomach, and a second portion comprises guaifenesin in a sustained release form, wherein the drug product contains 600 mg of guaifenesin and provides a mean C.sub.max and at least one of a mean AUC.sub.inf and a mean AUC.sub.0-12 for guaifenesin under fasted conditions based on single-dose administration that are from 80% to 125% of the mean C.sub.max and at least one of the mean AUC.sub.inf and the mean AUC.sub.0-12 for guaifenesin provided by a bi-layer tablet containing 600 mg of guaifenesin and having an immediate release layer consisting essentially of about 105.25 mg of guaifenesin dc, about 58.75 mg of microcrystalline cellulose, about 15 mg of sodium starch glycolate, and about 0.5 mg of magnesium stearate, and a sustained release layer consisting essentially of about 526.35 mg of guaifenesin dc, about 12.5 mg of hydroxypropyl methyl cellulose, about 6.25 mg of carbomer 934P, about 2.85 mg of magnesium stearate, and a colorant, and wherein guaifenesin is absorbed into bloodstream such that the drug product can be appropriately dosed once in a 12-hour period. 6. The drug product according to claim 5, wherein the mean C.sub.max and at least one of the mean AUC.sub.inf and the mean AUC.sub.0-12 for guaifenesin provided by the drug product are from 80% to 125% of the mean C.sub.max and at least one of the mean AUC.sub.inf and the mean AUC.sub.0-12 for guaifenesin provided by the bi-layer tablet at a 90% confidence interval. 7. The drug product according to claim 5, wherein the first and second portions are discrete. 8. The drug product according to claim 7, which is in a form of a bi-layer tablet. 9. The drug product according to claim 3, wherein the first portion is provided as a coating on the second portion. 10. The drug product according to claim 3, which is in a form of a capsule having beads. 11. The drug product according to claim 7, wherein the first portion is provided as a coating on the second portion. 12. The drug product according to claim 7, which is in a form of a capsule having beads.